After a bruising 2024, Blue Cross Blue Shield of Michigan is reporting improved — though still negative — financial results for 2025.
The Detroit-based nonprofit insurer released full-year 2025 figures showing a net loss of approximately $246 million, a sharp improvement from the roughly $1 billion loss posted in 2024.
Revenue for 2025 totaled about $43.3 billion, up from the prior year.
The numbers represent a meaningful move in the right direction. But they stop well short of a full turnaround.
Losses Narrowed, But Not Eliminated
The company’s core insurance business — known as underwriting — continued to operate at a loss in 2025. Blue Cross reported an underwriting deficit of about $975 million, meaning it paid out more in medical and pharmacy claims than it collected in premiums.
However, that underwriting loss was significantly smaller, percentage-wise, than in 2024, when medical cost spikes pushed the company deeply into the red.
The improved bottom line in 2025 was helped by:
-
Internal cost reductions of more than $400 million
-
Pricing adjustments
-
Stronger investment income, which generated roughly $600 million
In short, management tightened operations and benefited from market returns, helping offset still-elevated claims expenses.
Medical and Drug Costs Still Climbing
Even with improved results, the company made clear that health care cost pressures remain intense.
Combined medical and pharmacy claims rose by approximately $2.6 billion more than the year before, driven by higher use of hospital care, outpatient services, and high-cost prescription drugs — including specialty medications and weight-loss therapies.
That dynamic continues to challenge insurers across the country, not just in Michigan.
Membership remained relatively stable at about 5.1 million members, with some growth in Medicare Advantage and individual Affordable Care Act plans.
A Turn in the Right Direction — Not a Celebration
The 2025 results reflect stabilization after what company leadership previously described as unprecedented cost spikes in 2024. Losses narrowed substantially, operating margins improved, and overall financial performance strengthened.
But the company is still operating at a net loss, and health care inflation continues to run hot.
For policyholders and employers, that underlying reality remains the central issue: medical and pharmacy costs are still rising faster than anyone would like, and insurers are working to keep pace.
So yes — the numbers show progress. The trajectory is better than a year ago.
But with nearly a quarter-billion dollars still in the red and billions more in claims flowing out the door, this is a correction, not a comeback.
Blue Cross appears to have steadied the ship.
The waters, however, remain rough.
